文献速递MDS 与骨髓增殖性肿瘤

Selinexor联合芦可替尼治疗JAK抑制剂初治骨髓纤维化:III期SENTRY试验

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
PubMed 文献 · J Clin Oncol · 2026-06-02

SENTRY是一项双盲III期试验,353例JAK抑制剂初治骨髓纤维化患者按2:1随机接受Selinexor联合芦可替尼或安慰剂联合芦可替尼。

要点

  • Selinexor联合芦可替尼显著提高24周脾脏体积缩小≥35%的比例。
  • 症状评分共同主要终点未达标,两组间无显著差异。
  • 联合组≥3级不良事件更常见,主要为贫血、血小板减少和中性粒细胞减少。

核心结论

  • 在JAK抑制剂初治骨髓纤维化患者中,Selinexor联合芦可替尼达到SVR35共同主要终点但未达到AbsTSS共同主要终点。
  • 观察到早期OS差异,联合组安全性特征与各单药已知不良事件谱一致。

研究设计与样本

  • 双盲、III期随机对照试验,患者按2:1随机接受Selinexor联合芦可替尼或安慰剂联合芦可替尼。
  • 共353例JAK抑制剂初治骨髓纤维化患者入组。
  • 共同主要终点为第24周脾脏体积缩小≥35%(SVR35)和总症状评分(排除疲劳)自基线的绝对平均变化(AbsTSS)。

主要发现

  • SVR35差异在第12周即显现并持续至第36周。
  • AbsTSS共同主要终点未达标,但两组症状评分均较基线改善(联合组-9.9,安慰剂组-10.9),组间无显著差异。
  • ≥3级不良事件发生率联合组为70.1%,安慰剂组为50.0%,最常见为贫血、血小板减少和中性粒细胞减少;恶心在联合组更频繁但主要为低级别且出现较早。

关键数值与推荐

  • SVR35定义:第24周脾脏体积较基线缩小≥35%。
  • AbsTSS定义:总症状评分(排除疲劳)自基线至第24周的绝对平均变化。

临床怎么用

  • 对于JAK抑制剂初治骨髓纤维化患者,Selinexor联合芦可替尼可考虑用于提高脾脏体积缩小率。
  • 联合方案未显示症状评分额外获益,且≥3级血液学不良事件增加,需加强血细胞计数监测。

局限性

  • AbsTSS共同主要终点未达到,症状改善方面未见联合组优势。
  • OS分析中位随访约12个月,数据尚不成熟,名义P值需谨慎解读。
  • 联合组≥3级不良事件发生率更高,可能影响长期耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ruxolitinib improves splenomegaly and symptoms in myelofibrosis (MF) but lacks reliable clonal burden reduction. Selinexor, an oral inhibitor of exportin 1, has demonstrated activity in MF. We evaluated selinexor plus ruxolitinib versus ruxolitinib alone in Janus kinase inhibitor-naïve MF. METHODS: In this double-blind, phase III trial, patients were randomly assigned (2:1) to receive selinexor plus ruxolitinib or placebo plus ruxolitinib. Coprimary end points were spleen volume reduction ≥35% (SVR35) and absolute mean change in total symptom score (AbsTSS; excluding fatigue) from baseline to week 24. RESULTS: A total of 353 patients were randomly assigned. At week 24, SVR35 was achieved in 49.8% of the selinexor plus ruxolitinib group versus 28.0% of the placebo plus ruxolitinib group (difference, 21.8 percentage points; odds ratio, 2.58 [95% CI, 1.60 to 4.17]; P < .0001). Differences were evident by week 12 and through week 36. The AbsTSS coprimary end point was not met; however, symptom scores improved from baseline in both groups (-9.9 selinexor plus ruxolitinib, -10.9 placebo plus ruxolitinib), with no significant between-group difference. At a median follow-up of approximately 12 months, the overall survival (OS) hazard ratio was 0.43 ([95% CI, 0.19 to 1.00]; nominal P = .022). Grade ≥3 adverse events (AEs) occurred in 70.1% and 50.0% of patients in the selinexor plus ruxolitinib or placebo plus ruxolitinib groups, respectively, most commonly anemia, thrombocytopenia, and neutropenia. Nausea was more frequent with selinexor but predominantly low-grade and early. CONCLUSION: In patients with JAK inhibitor-naïve MF, selinexor plus ruxolitinib met its coprimary end point of improved SVR35 but did not meet the AbsTSS coprimary end point, compared with placebo plus ruxolitinib. An early OS difference was observed. The safety profile was consistent with known AE profiles of the individual agents.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bose P, Ali H, Al-Ali HK, et al. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial. J Clin Oncol. 2026. PMID: 42227656. doi:10.1200/JCO-26-01080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。